Published in Br J Pharmacol on October 01, 1985
A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol (1987) 0.88
Dopamine released from nerve terminals activates prejunctional dopamine receptors in dog mesenteric arterial vessels. Br J Pharmacol (1987) 0.80
Dopamine actions in vitro on enzyme and electrolyte secretion from normal and sympathectomized rat parotid glands. J Physiol (1988) 0.75
Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev (1972) 5.07
Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-Hydroxydopamine. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 4.85
ELUCIDATION OF THE RATE-LIMITING STEP IN NOREPINEPHRINE BIOSYNTHESIS IN THE PERFUSED GUINEA-PIG HEART. J Pharmacol Exp Ther (1965) 3.45
Pharmacological actions of 6-hydroxydopamine. Pharmacol Rev (1974) 2.32
Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther (1969) 2.11
Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. J Pharmacol Exp Ther (1970) 1.69
ANTAGONISM OF CERTAIN EFFECTS OF CATECHOLAMINE-DEPLETING AGENTS BY ANTIDEPRESSANT AND RELATED DRUGS. J Pharmacol Exp Ther (1964) 1.49
Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure. Science (1969) 1.43
A comparison of the vascular dopamine receptor with other dopamine receptors. Annu Rev Pharmacol Toxicol (1978) 1.41
Dopamine-containing vasomotor nerves in the dog kidney. J Neurochem (1978) 1.36
Tyrosine hydroxylase. Pharmacol Rev (1966) 1.33
Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications. J Auton Pharmacol (1982) 1.20
Dopamine and noradrenaline levels in peripheral tissues of several mammalian species. J Neurochem (1981) 1.05
Histofluorescence techniques provide evidence for dopamine-containing neuronal elements in canine kidney. Science (1979) 0.99
Dopamine-containing axons supplying the arterio-venous anastomoses of the canine paw pad. J Neurochem (1978) 0.98
Dopamine and norepinephrine in noradrenergic axons: a study in vivo of their precursor product relationship by mass fragmentography and radiochemistry. Pharmacol Rev (1972) 0.90
Evidence for a widely distributed peripheral dopaminergic system. Fed Proc (1983) 0.84
Differentiation of dopaminergic and noradrenergic neurons in rat spinal cord. J Neurochem (1978) 0.84
Evidence for the existence of peripheral dopaminergic neurons. Brain Res (1980) 0.84
Presynaptic dopamine receptors as mediators of dopamine-induced inhibition of neurogenic vasoconstriction. Eur J Pharmacol (1977) 0.84
Pharmacological investigations of the vasodilator nerves supplying the duck's foot. Br J Pharmacol (1984) 0.81
The occurrence and functional significance of dopamine in some peripheral adrenergic nerves of the rat. Naunyn Schmiedebergs Arch Pharmacol (1973) 0.81
Catabolism of endogenous dopamine in peripheral tissues: is there an independent role for dopamine in peripheral neurotransmission? J Neurochem (1982) 0.80
3H-spiroperidol binding sites in the rabbit superior mesenteric artery. A histoautoradiographic study. Pharmacology (1984) 0.78
Effect of 6-hydroxydopamine on bovine adrenal chromaffin cells in culture. Br J Pharmacol (1983) 0.77
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res (2010) 1.14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem (1999) 1.14
Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol (2007) 1.12
Apical and basal uptake of L-dopa and L-5-HTP and their corresponding amines, dopamine and 5-HT, in OK cells. Am J Physiol (1997) 1.04
Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci (2002) 1.04
Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand (2009) 1.01
Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia (2001) 0.99
Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res (2001) 0.98
Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol (2002) 0.98
Deamination of newly-formed dopamine in rat renal tissues. Br J Pharmacol (1991) 0.97
Defective D1-like receptor-mediated inhibition of the Cl-/HCO3- exchanger in immortalized SHR proximal tubular epithelial cells. Am J Physiol Renal Physiol (2004) 0.95
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods Find Exp Clin Pharmacol (2009) 0.94
Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation. Mol Pharmacol (2006) 0.94
Role of cAMP-PKA-PLC signaling cascade on dopamine-induced PKC-mediated inhibition of renal Na(+)-K(+)-ATPase activity. Am J Physiol Renal Physiol (2002) 0.93
Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol (1986) 0.92
Effects of 6-hydroxydopamine on dopamine and noradrenaline content in dog blood vessels and heart. Evidence for a noradrenaline-independent dopamine pool. Naunyn Schmiedebergs Arch Pharmacol (1985) 0.89
Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther (2008) 0.89
Effects of MAO-A and MAO-B selective inhibitors Ro 41-1049 and Ro 19-6327 on the deamination of newly formed dopamine in the rat kidney. J Pharmacol Exp Ther (1990) 0.89
A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol (1987) 0.88
Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther (2008) 0.88
Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res (2011) 0.87
Type A and B monoamine oxidase activities in the human and rat kidney. Acta Physiol Scand (1992) 0.87
Endogenous dopamine modulates jejunal sodium absorption during high-salt diet in young but not in adult rats. Gastroenterology (1994) 0.87
Dopamine formation, from its immediate precursor 3,4-dihydroxyphenylalanine, along the rat digestive tract. Fundam Clin Pharmacol (1993) 0.87
Evidence for an extraneuronal location of monoamine oxidase in renal tissues. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.87
Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology (1999) 0.86
The renal handling of dopamine originating from L-dopa and gamma-glutamyl-L-dopa. Br J Pharmacol (1994) 0.86
Opossum kidney cells take up L-DOPA through an organic cation potential-dependent and proton-independent transporter. Cell Biol Int (1997) 0.86
Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol (2007) 0.86
Effects of denervation induced by 6-hydroxydopamine on cell nucleus activity of arterial and cardiac cells of the dog. J Auton Pharmacol (1987) 0.85
Dopamine D2 receptor polymorphisms in inflammatory bowel disease and the refractory response to treatment. Dig Dis Sci (2006) 0.85
Role of nitric oxide in the activation of NF-kappaB, AP-1 and NOS II expression in articular chondrocytes. Inflamm Res (2002) 0.84
In vivo effects of the monoamine oxidase inhibitors Ro 41-1049 and Ro 19-6327 on the production and fate of renal dopamine. J Neural Transm Suppl (1994) 0.84
Expression of LAT1 and LAT2 amino acid transporters in human and rat intestinal epithelial cells. Amino Acids (2005) 0.84
Diphenyleneiodonium inhibits NF-kappaB activation and iNOS expression induced by IL-1beta: involvement of reactive oxygen species. Mediators Inflamm (2001) 0.84
Renal dopaminergic mechanisms in renal parenchymal diseases and hypertension. Nephrol Dial Transplant (2001) 0.84
Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor. Drug Metab Dispos (2003) 0.83
Regulatory pathways and uptake of L-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cells. Am J Physiol Cell Physiol (2001) 0.83
Renal and intestinal autocrine monoaminergic systems: dopamine versus 5-hydroxytryptamine. Clin Exp Hypertens (1997) 0.83
L-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4. Brain Res (1999) 0.83
Healthy subjects volunteering for Phase I studies: influence of curiosity, exploratory tendencies and perceived self-efficacy. Int J Clin Pharmacol Ther (2008) 0.83
Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells. Kidney Int (2004) 0.83
Oxidative stress and alpha1-adrenoceptor-mediated stimulation of the Cl-/HCO3- exchanger in immortalized SHR proximal tubular epithelial cells. Br J Pharmacol (2008) 0.83
Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology (1999) 0.83
Modulation of insulin transport in rat brain microvessel endothelial cells by an ecto-phosphatase activity. J Cell Biochem (2002) 0.83
Hydrogen peroxide mediates interleukin-1beta-induced AP-1 activation in articular chondrocytes: implications for the regulation of iNOS expression. Cell Biol Toxicol (2003) 0.82
Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res (1999) 0.82
Studies on the pharmacology of the inward transport of L-DOPA in rat renal tubules. Br J Pharmacol (1996) 0.82
Effect of type A and B monoamine oxidase selective inhibition by Ro 41-1049 and Ro 19-6327 on dopamine outflow in rat kidney slices. Br J Pharmacol (1994) 0.81
Opossum kidney (OK) cells in culture synthesize and degrade the natriuretic hormone dopamine: a comparison with rat renal tubular cells. Int J Biochem Cell Biol (1997) 0.81
Deficiency of renal dopaminergic-dependent natriuretic response to acute sodium load in black salt-sensitive subjects in contrast to salt-resistant subjects. J Hypertens (1999) 0.81
Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther (2009) 0.81
Monoamine oxidase and semicarbazide-sensitive amine oxidase kinetic analysis in mesenteric arteries of patients with type 2 diabetes. Physiol Res (2010) 0.81
Dopamine released from nerve terminals activates prejunctional dopamine receptors in dog mesenteric arterial vessels. Br J Pharmacol (1987) 0.80
A comparison of the action of the endothelium-derived relaxant factor and the inhibitory factor from the bovine retractor penis on rabbit aortic smooth muscle. Br J Pharmacol (1986) 0.80
Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-DOPA uptake. Acta Physiol Scand (2004) 0.80
Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat. Br J Pharmacol (1995) 0.80
Alpha2-adrenoceptors mediate the effect of dopamine on adult rat jejunal electrolyte transport. Eur J Pharmacol (1998) 0.80
Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat. Neuropharmacology (1990) 0.80
Lamotrigine analysis in blood and brain by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (2001) 0.80
Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand (2009) 0.80
Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol (1996) 0.80
Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission. J Neurochem (1992) 0.79
Influence of administration vehicles and drug formulations on the pharmacokinetic profile of lamotrigine in rats. Fundam Clin Pharmacol (2002) 0.79
Crystallization and preliminary crystallographic characterization of catechol-O-methyltransferase in complex with its cosubstrate and an inhibitor. Acta Crystallogr D Biol Crystallogr (2001) 0.79
Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol (2015) 0.79
Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol (2001) 0.79
Intestinal 5-hydroxytryptamine and mast cell infiltration in rat experimental colitis. Dig Dis Sci (2006) 0.79
Personality characteristics of volunteers in Phase 1 studies and likelihood of reporting adverse events. Int J Clin Pharmacol Ther (2008) 0.79
Neurotoxicity and induction of fibroblast proliferation by acetaldehyde in the rabbit liver. J Auton Pharmacol (1993) 0.79
Fibroblasts and sympathetic innervation of blood vessels. Blood Vessels (1985) 0.79
D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors. Kidney Int (2001) 0.79
Caco-2 cells in culture synthesize and degrade dopamine and 5-hydroxytryptamine: a comparison with rat jejunal epithelial cells. Life Sci (1999) 0.79
Effects of chemical sympathectomy on dopamine and noradrenaline content of the dog gastrointestinal tract. J Auton Pharmacol (1985) 0.79
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. Eur J Neurol (2015) 0.79
Ontogenic aspects of D1 receptor coupling to G proteins and regulation of rat jejunal Na+, K+ ATPase activity and electrolyte transport. Br J Pharmacol (2000) 0.78
Expression and characterization of rat soluble catechol-O-methyltransferase fusion protein. Protein Expr Purif (2001) 0.78
Regulation of [(3)H]MPP(+) transport by phosphorylation/dephosphorylation pathways in RBE4 cells: role of ecto-alkaline phosphatase. Naunyn Schmiedebergs Arch Pharmacol (2002) 0.78
Monoamine oxidase activities in human cystic and colonic arteries--influence of age. J Neural Transm Suppl (1998) 0.78
Renal aging in WKY rats: changes in Na+,K+ -ATPase function and oxidative stress. Exp Gerontol (2010) 0.78
Salt intake and sensitivity of intestinal and renal Na+-K+ atpase to inhibition by dopamine in spontaneous hypertensive and Wistar-Kyoto rats. Clin Exp Hypertens (2000) 0.78
Acute hypotensive, natriuretic, and hormonal effects of nifedipine in salt-sensitive and salt-resistant black normotensive and hypertensive subjects. J Cardiovasc Pharmacol (1999) 0.78
A new approach on the purification of recombinant human soluble catechol-O-methyltransferase from an Escherichia coli extract using hydrophobic interaction chromatography. J Chromatogr A (2007) 0.78
Are fibroblasts adrenergically innervated cells? Blood Vessels (1981) 0.78
Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J Pharmacol Exp Ther (1997) 0.77
Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. Eur J Clin Pharmacol (2006) 0.77
Adverse non-drug-related complaints by healthy volunteers in Phase I studies compared to the healthy general population. Int J Clin Pharmacol Ther (2008) 0.77
Dopamine D2-like receptors in the rat kidney: effect of denervation. Eur J Pharmacol (1997) 0.77
Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. Fundam Clin Pharmacol (2005) 0.77
[Drug activation of GABAergic transmission in the central nervous system: benzodiazepines and GABAergic agonists]. Acta Med Port (1985) 0.77
The actions of 5-hydroxytryptamine receptor agonists and antagonists at pre- and postjunctional level on the canine saphenous vein. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.77
Na+-independent transporters, LAT-2 and b0,+, exchange L-DOPA with neutral and basic amino acids in two clonal renal cell lines. J Membr Biol (2002) 0.77
Role of monoamine oxidase and catechol-O-methyltransferase in the metabolism of renal dopamine. J Neural Transm Suppl (1994) 0.77
Changes in the subcellular distribution of the rat uterus oestrogen receptor as induced by oestradiol, tamoxifen and ZD 182,780. J Pharm Pharmacol (1996) 0.77
Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease. Kidney Blood Press Res (1998) 0.77
Regional intestinal adaptations in Na+,K+-ATPase in experimental colitis and the contrasting effects of interferon-gamma. Acta Physiol Scand (2005) 0.77
Intestinal dopaminergic activity in obese and lean Zucker rats: response to high salt intake. Clin Exp Hypertens (2002) 0.77
Role of monoamine oxidase A and B in the deamination of newly-formed dopamine in the rat kidney. J Neural Transm Suppl (1990) 0.77
Ca2+/calmodulin mediated pathways regulate the uptake of L-DOPA in mouse neuroblastoma neuro 2A cells. Life Sci (2000) 0.77